Antithrombotic drugs, which include antiplatelet and anticoagulant therapies, prevent and
treat many cardiovascular disorders and, as such, are some of the most commonly …

This chapter focuses on new antithrombotic drugs that are in phase II or III clinical testing.
Development of these new agents was prompted by limitations of existing antiplatelet …

This article focuses on new antithrombotic drugs that are in or are entering phase 3 clinical
testing. Development of these new agents was prompted by the limitations of existing …

Thrombosis, both venous and arterial, is a major cause of morbidity and mortality worldwide.
Consequently, there is an ongoing search for new antithrombotic drugs, particularly novel …

Thromboembolic disorders are among the major causes of morbidity and mortality, and
anticoagulation remains the cornerstone of prevention and treatment of these disorders …

New oral antithrombotics: a need for laboratory monitoring. For - ScienceDirect Skip to main
contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF …

Recent advances in our understanding of the contribution of thrombin generation to arterial
thrombosis and the role of platelets in venous thrombosis have prompted new treatment …

New oral anticoagulants (OACs) that directly inhibit Factor Xa (FXa) or thrombin have been
developed for the long-term prevention of thromboembolic disorders. These novel agents …

The article describes the mechanisms of action, pharmacokinetics, and pharmacodynamics
of aspirin, dipyridamole, cilostazol, the thienopyridines, and the glycoprotein IIb/IIIa …

Background The objective of this article is to summarize the published literature concerning
the pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently …